Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-01-08
2008-01-08
Hui, San-ming (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07317001
ABSTRACT:
The invention features a method of treating or preventing a disease associated with the use of antibiotics in a patient in need thereof by administering to the patient ramoplanin in an amount and for a duration effective to treat said disease. The disease may be caused, for example, by the presence of a bacterium such as enterotoxin producing strains ofC. difficile, C. perfringens, orS. aureus.
REFERENCES:
patent: 4303646 (1981-12-01), Cavalleri et al.
patent: 4328316 (1982-05-01), Cavalleri et al.
patent: 4427656 (1984-01-01), Cavalleri et al.
patent: 5108988 (1992-04-01), Ciabatti et al.
patent: 5491128 (1996-02-01), Ciabatti et al.
patent: 5539087 (1996-07-01), Restelli et al.
patent: 5752941 (1998-05-01), Romano' et al.
patent: 5925550 (1999-07-01), Lancini et al.
patent: WO 99/30690 (1999-06-01), None
patent: WO 01/44271 (2001-06-01), None
patent: WO 01/44272 (2001-06-01), None
patent: WO 01/44274 (2001-06-01), None
patent: WO 01/53330 (2001-07-01), None
patent: WO 01/70213 (2001-09-01), None
patent: WO 01/97851 (2001-12-01), None
patent: WO 02/05838 (2002-01-01), None
patent: WO 02/15959 (2002-02-01), None
patent: WO 02/056829 (2002-07-01), None
patent: WO 02/059145 (2002-08-01), None
patent: WO 02/059322 (2002-08-01), None
Biavasco et al., Antimicrobial Agents and Chemotherapy, 1991; 35(1): 195-197.
Baden et al., “Molecular characterization of vancomycin-resistant enterococci repopulating the gastrointestinal tract following treatment with a novel glycolipodepsipeptide, ramoplanin,”J. Clinical Microbiol., 40:1160-1163 (2002).
Bartoloni et al., “Comparative in vitro activity of MDL 62211 against gram-positive bacteria,” 29thInterscience Conference on Antimicrobial Agents and Chemotherapy, Abstract (1989).
Bartoloni et al., “In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents againststaphylococci, enterococciandClostridium difficile,” J. Antimicrobial Chomotherapy26:627-633 (1990).
Bartoloni et al., “In vitro activity of MDL 62,879 against gram-positive bacteria and bacteroides species,”Eur. J. Clin. Microbiol. Infect. Dis.14:1105-108 (1995).
Bartoloni et al., “In vitro activity of MDL 62,879 againstClostridium difficile, Propionibacterium acnes, Bacteroides fragilisandBacteroidesspp.,”Interscience Conference on Antimicrobial Agents and Chemotherapy(Abstract F-117) 1995.
Citron et al., “In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria,”Antimicrobial Agents and Chemotherapy47:2334-2338 (2003).
Fekety et al., “In vitro susceptibility ofClostridium difficileto Ramoplanin R.,” 32ndInterscience Conference on Antimicrobial Agents and Chemotherapy(Abstract 490) 1992.
Hassan et al., “In vitro activity of teicoplanin, vancomycin, A16686, clindamycin, erythromycin and fusidic acid against anaerobic bacteria,”Singapore Med. J.31:56-58 (1990).
Jabes et al., “Superior efficacy of short treatment duration of ramoplanin over vancomycin in the hamster model ofC. difficileassociated colitis,”43rdAmerican Society for Microbiology(Abstract B-328) 2003.
Neu et al., “In vitro activity of A-16686, a new glycopeptide,”Chemotherapy32:453-457 (1986).
O'Hare et al., “In vitro activity of A-16686—A novel glycopeptide active against gram positive bacteria,”15thInternational Congress of Chemotherapy, (Abstract 390) 1987.
O'Hare et al., “In-vitro studies with ramoplanin (MDL 62, 198): a novel lipoglycopeptide antimicrobial,”J. Antimicrobial Chemotherapy25:217-220 (1990).
Peláez et al. “In vitro activity of ramoplanin againstClostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole,”43rdInterscience Conference on Antimicrobial Agents and Chemotherapy(Abstract E-2188) 2003.
Ravizzola et al., “Attivita' antibatterica di un nuovo glicopeptide A-16686 nei confronti di microorganismi gram-positivi,”Biol. Microbial. Lab4:51-56 (1987). (English abstract).
Ravizzola et al., A-16686, a new glycopeptide: in vitro evaluation in comparison with other antibiotics,J. Chemother.1(Suppl. 4):212-213 (1989).
Romano et al., Bactericidal activity of ramoplanin (RA) againstClostridiumsp. 41stInterscience Conference on Antimicrobial Agents and Chemotherapy(Abstract E-2260) 2001.
Wilcox et al., “Surveillance for resistance to metronidazole, vancomycin or ramoplanin in genotypically distinct and clonalClostridium difficilestrains,” 43rdInterscience Conference on Antimicrobial Agents and Chemotherapy(Abstract E-2190) 2003.
Wong et al., “Effective suppression of vancomycin-resistantEnteroccusspecies in asymptomatic gastrointestinal carriers by a novel glycolipodepsipeptide, ramoplanin,”Clin. Infect. Dis.33:1476-1482 (2001).
Bartlett, “Treatment of antibiotic-associated pseudomembranous colitis,”Reviews of Infectious Diseases6(Suppl 1):S235-S241 (1984).
Biavasco et al., “In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates ofClostridium difficile,” Antimicrobial Agents and Chemotherapy35:195-197 (1991).
Dworczynski et al., “Susceptibility ofClostridium difficileStrains o Teicoplanin and Ramoplanin,”Otrzymano7:486 (1993).
Romeo et al., “Repeated Doses of Ramoplanin Orally Administered to Healthy Male Volunteers: Tolerability, Lack of Absorption and Effect on the Stool Microflora,” Abstract No. 448, Session 40, Abstracts of the 33rdICAAC (1993).
de Lalla et al., “Oral Ramoplanin (R) Single-Dose Administration in Pseudomembranous Colitis (PMC),” Abstract No. 4102,Can. J. Infect. Dis.6 (suppl. C):4526 (1995).
Bowie, W.R., et al., “Failure of Norfloxacin to EradicateChlamydia trachomatisin Nongonococcal Urethritis,”Antimicrobial Agents and Chemotherapy30(4):594-597 (1986).
Silverman, J.A., et al., “Inhibition of Daptomycin by Pulmonary Surfactant: In Vitro Modeling and Clinical Impact,”Journal of Infectious Diseases191:2149-2152 (2005).
Mégraud, F., et al., “Bactericidal Effect of Amoxicillin onHelicobacter pyloriin an In Vitro Model Using Epithelial Cells,”Antimicrobial Agents and Chemotherapy35(5):869-872 (1991).
McFarland, L.V., “Alternative Treatments forClostridium difficileDisease: What Really Works?”Journal of Medical Microbiology54:101-111 (2005).
Declaration of Daniela Jabes, Ph.D. Under 37 C.F.R. § 1.132, dated Apr. 30, 2007.
Declaration Pursuant to 37 C.F.R. § 1.132 by Thomas S. Leach Dated Jun. 14, 2007.
Jabes Daniela
Labaudiniere Richard F.
Leach Timothy S.
Mosconi Giorgio
Rauscher Steven M.
Hamilton Brook Smith & Reynolds P.C.
Hui San-ming
Oscient Pharmaceuticals Corporation
LandOfFree
Use of ramoplanin to treat diseases associated with the use... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of ramoplanin to treat diseases associated with the use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of ramoplanin to treat diseases associated with the use... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2789637